Updated Protocol for Clinical Trial Evaluating (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer Announced
“We are extremely excited about the updated combination study protocol and grateful for the significantly expanded support from Eli Lilly to run the trial,” said Steven Quay, M.D., Ph.D., Atossa’s President and Chief Executive Officer. “As we expected, and the preliminary EVANGELINE data has confirmed, the 80 mg dose of (Z)-endoxifen has a highly favorable safety profile and delivers the desired concentration levels to optimally target PKCβ1. We also know from both the 40 mg and 80 mg EVANGELINE cohorts that premenopausal women treated with (Z)-endoxifen experience profound clinical benefit without the need for ovarian suppression. Further validating this with a head-to-head comparison of data from the two cohorts in the combination study will be extremely valuable as we continue conversations with prospective partners and regulators.”
Share:
More News
“Initiation of the TEADCO Phase 1b/2 basket trial is another important milestone for the ODM-212 clinical development program and reflects our commitment to patients with difficult-to-treat cancers,” said Professor Outi Vaarala, Executive Vice President, Research & Development at Orion. “Together with the ongoing TEADES study, TEADCO highlights the versatility of
“In this study, tovecimig showed an impressive overall response rate which translated into a clinically meaningful and highly statistically significant improvement in PFS for patients with previously treated BTC. The remarkable 56% reduction in the risk of disease progression is unprecedented in this patient population without an actionable mutation in
“We are encouraged to see taletrectinib (IBTROZI) added to the NCCN Guidelines® for CNS Cancers given its demonstrated high rates of intracranial response that are durable in ROS1+ NSCLC patients with brain metastases,” said David Hung, M.D., Founder, President and Chief Executive Officer of Nuvation Bio. “Given the prevalence of
Daniel Getts, Ph.D., CEO of CREATE, added “MT-304 is proof of what our platform can do, and what our team can execute. Our mRNA-LNP leadership enables us to move from concept to clinic with remarkable speed. Just last weekend at AACR, we presented compelling preclinical data across our in vivo